Risk factors
Sunshine Biopharma (SBFM) risk factors
Item 1A of every Sunshine Biopharma Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors12 risks2 new2 dropped3 reworded
Accumulated deficit grew to $75,015,126 alongside ongoing net losses. Supplier concentration increased with 75% of drug portfolio manufactured by three overseas suppliers. Nasdaq compliance remains precarious despite trading slightly above the $1.00 minimum bid price.
Filed Apr 03, 2026 - FY2024 10-K risk factors12 risks
Sunshine Biopharma relies heavily on lower-margin Canadian generic drugs through Nora Pharma while funding development of proprietary candidates.
Filed Apr 01, 2025